BackgroundCheck.run
Search For

Matthew Zhao, ~25Belmont Hills, PA

Matthew Zhao Phones & Addresses

Belmont Hills, PA   

New York, NY   

Social networks

Matthew Zhao

Linkedin

Mentions for Matthew Zhao

Resumes

Resumes

Matthew Zhao Photo 1

Matthew Zhao

Publications

Us Patents

Process For The Synthesis Of (2R, 2-Alpha-R, 3A)-2-[1-(3,5-Bis(Trifluoromethyl)Phenyl)Ethoxy]-3-(4-Fluorophenyl)-1, 4-Oxazine

US Patent:
6600040, Jul 29, 2003
Filed:
Jun 8, 2001
Appl. No.:
09/878042
Inventors:
Karel M. Jos Brands - Jersey City NJ
Karen M. Conrad - Clark NJ
Matthew M. Zhao - Edison NJ
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C07D295027
US Classification:
544174, 544170
Abstract:
The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.

Process For Making Spiro Isobenzofuranone Compounds

US Patent:
6924291, Aug 2, 2005
Filed:
Jan 22, 2002
Appl. No.:
10/054413
Inventors:
Matthew Mangzhu Zhao - Edison NJ,
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K031/44
US Classification:
514278, 514409, 514407, 514397, 514314, 514302, 514275, 51425301
Abstract:
This invention relates to a process for making spiro isobenzofuranone compounds by coupling of an aminopyrazine fragment with a spirolactone piece.

Crystalline Forms Of An Inhibitor Of 11-Β-Hydroxysteroid Dehydrogenase Type 1

US Patent:
7875642, Jan 25, 2011
Filed:
Jan 21, 2005
Appl. No.:
10/587110
Inventors:
Yuri Bereznitski - South River NJ,
Mark A. Huffman - Warren NJ,
Joseph E. Lynch - Plainfield NJ,
Matthew Zhao - Edison NJ,
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/4196
C07D 249/08
US Classification:
514383, 5482622
Abstract:
Novel crystalline salts of 3-[1-(4-chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole are potent inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.

Solid Forms Of (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-Ethoxybenzyl)Phenyl)-6-(Methylthio)Tetrahydro-2H-Pyran-3,4,5-Triol And Methods Of Their Use

US Patent:
8217156, Jul 10, 2012
Filed:
Jul 15, 2009
Appl. No.:
12/503225
Inventors:
Susan Margaret De Paul - Zürich,
Anett Perlberg - Gunzgen,
Matthew Mangzhu Zhao - Edison NJ,
Assignee:
Lexicon Pharmaceuticals, Inc. - The Woodlands TX
International Classification:
C07H 15/203
C07H 5/10
US Classification:
536 184, 536 41
Abstract:
Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders.

Trans-Glycosidation Process For The Synthesis Of (2R, 2-Alpha-R, 3A) -2-(1- (3,5-Bis(Trifluoromethyl) Phenyl) Ethoxy ) -3- (4-Fluorophenyl) -1, 4-Oxazine

US Patent:
2002002, Feb 21, 2002
Filed:
Jun 8, 2001
Appl. No.:
09/878043
Inventors:
James McNamara - Fanwood NJ,
Matthew Zhao - Edison NJ,
International Classification:
C07D265/32
US Classification:
544/174000
Abstract:
The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.

Active Salt Forms With Tyrosine Kinase Activity

US Patent:
2004002, Feb 5, 2004
Filed:
Jun 26, 2003
Appl. No.:
10/607031
Inventors:
Yu Ren - North Wales PA,
Shyam Karki - Lansdale PA,
Matthew Zhao - Edison NJ,
Mark Bilodeau - Lansdale PA,
International Classification:
A61K031/496
C07D417/14
US Classification:
514/253100, 544/360000
Abstract:
The present invention relates to orally active salt forms of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

Salt Forms With Tyrosine Kinase Activity

US Patent:
2004002, Feb 5, 2004
Filed:
Jun 26, 2003
Appl. No.:
10/607114
Inventors:
Yu Ren - North Wales PA,
Shyam Karki - Lansdale PA,
Matthew Zhao - Edison NJ,
International Classification:
A61K031/496
C07D417/14
US Classification:
514/253100, 544/360000
Abstract:
The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

Methods Of Treating Diabetes

US Patent:
2013016, Jun 27, 2013
Filed:
Jun 22, 2012
Appl. No.:
13/530645
Inventors:
Susan Margaret De PAUL - Zurich,
Anett PERLBERG - Gunzgen,
Matthew Mangzhu ZHAO - Edison NJ,
International Classification:
C07H 7/04
US Classification:
514 24
Abstract:
Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.